image credit- shutterstock
On March 26, Microsoft (MS) CEO Satya Nadella arrived in Korea for the Microsoft AI Tour in Seoul, a forum that brought together Korean firms involved in Microsoft’s AI ecosystem to present their model use cases to participants.
Among healthcare companies, Seegene, a Korean diagnostics solutions company, showcased its use of Microsoft’s artificial intelligence (AI) technologies in expediting diagnostic reagent development processes during the forum.
During a panel discussion focused on the healthcare industry, Seegene introduced its plans to leverage Microsoft's Azure OpenAI Service in its diagnostic reagent development processes. Azure OpenAI provides API access to OpenAI’s language models, such as GPT-4, through Microsoft’s secure cloud platform, Azure—enabling developers to integrate AI functions into their applications.
Seegene OneSystem is an open, technology-sharing platform that combines Seegene’s proprietary syndromic quantitative PCR technology with over two decades of diagnostic innovation. By partnering with leading global companies, the platform enables the co-development of localized diagnostic products, helping make PCR testing a routine part of life and advancing the vision of a world free from all diseases.
Baek Young-seok, Head of Strategy and Planning, Seegene, said "Seegene aims to expand global research network using AI and cloud technologies and develop more than 1,000 diagnostic reagents simultaneously. We plan to accelerate new drug development with more precise data analysis and In-silico (computer-based simulation) technology. Seegene will continue synergic collaboration with MS and bring innovative changes in healthcare industry and pave the way for firm foundation for future medical innovation.”
